PMC7683151_01
Case 1. Optical coherence tomographic images and fundus photographs showing the central retinal thickness (CRT) pre (A, B), at 1 month (M) (C, D), 6 M (E, F), and 30 M (G, H) after commencing the oral sodium-glucose cotransporter 2 inhibitor (SGLT2i).
CRIOPM2020-8867079.001.jpg
PMC7683151_01_CRIOPM2020-8867079.001.jpg
fig1
The macular edema in the left eye persisted for 4 years with a decimal BCVA of 0.3 and a central retinal thickness (CRT) of 598 mum (Figure 1(B)). Six months later, the macular edema was completely resolved (Figure 1(D)). SGLT2 inhibitor treatment. Six months later (Figure 1(F)), her body weight was reduced, and the glycemic control was improved with the glycated hemoglobin A1c of 6.5% (Table 1). The clinical course of the macular edema before and after the administration of the SGLT2 inhibitor is shown in Figure 1. The final decimal BCVA improved to 0.8, and the CRT measured by optical coherence tomography (OCT) was 235 mum (Figure 1(H)) at 30 months after commencing the SGLT2 inhibitor.
PMC7683151_02
Case 2. Optical coherence tomographic images and fundus photographs showing the central retinal thickness (CRT) pre (A, B) and at 2 months (M) (C, D), 3 M (E, F), 6 M (G, H), and 12 M (I, J) after commencing the oral sodium-glucose cotransporter 2 inhibitor (SGLT2i). A sub-Tenon injection of triamcinolone acetonide (STTA) was administered in her right eye at eight months.
CRIOPM2020-8867079.002.jpg
PMC7683151_02_CRIOPM2020-8867079.002.jpg
fig2
The CRT was 519 mum in the right eye and 467 mum in the left eye (Figure 2(A) and (B)). Two months later, the CRT was thinner in her left eye (Figure 2(D)), and six months later, the CRT was reduced to 491 mum in the right eye (Figure 2(G)) and 326 mum in the left eye (Figure 2(H)). The clinical course of the macular edema is shown in Figure 2. Her final BCVA was 0.8 in the right eye and 0.4 in the left eye, and the CRT was 378 mum in the right (Figure 2(I)), 305 mum in the left (Figure 2(J)) at twelve months.
PMC7683151_03
Case 3. Optical coherence tomographic images and fundus photographs showing the central macular thickness (CRT) pre (A, B) and at 10 days (C, D), 1 month (M) (E, F), 3 M (G, H), and 6 M (I, J) after commencing the oral sodium-glucose cotransporter 2 inhibitor (SGLT2i).
CRIOPM2020-8867079.003.jpg
PMC7683151_03_CRIOPM2020-8867079.003.jpg
fig3
Despite these treatments, the CRT was still 613 mum in the right eye (Figure 3(A)) and 412 mum in the left eye (Figure 3(B)); although, the decimal BCVA was 1.0 in both eyes. Oral luseogliflozin 2.5 mg was administered, and the CRT of both eyes (Figure 3(C) and (D)) began to decrease by two weeks after commencing the luseogliflozin. Six months later, her CRT was reduced to 451 mum in the right eye (Figure 3(I)) and 273 mum in the left eye (Figure 3(J)).